• KOL
    • Bipolar Disorder
    • Gary S Sachs
    • Gary S Sachs: Influence Statistics

      Gary S Sachs

      Gary S Sachs

      Show email address

      Department of Psychiatry, Case Western Reserve School of Medicine, Cleveland, and University Hospitals Cleveland Medical Center, Cleveland (Calabrese); Intra-Cellular ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Gary S Sachs:Expert Impact

      Concepts for whichGary S Sachshas direct influence:Bipolar disorder,Bipolar depression,Patients bipolar disorder,Panic disorder,Bipolar patients,Rapid cycling,Bipolar disorder stepbd,Acute mania.

      Gary S Sachs:KOL impact

      Concepts related to the work of other authors for whichfor which Gary S Sachs has influence:Bipolar disorder,Atypical antipsychotics,Weight gain,Depressive symptoms,Mood stabilizers,Acute mania,Major depression.

      KOL Resume for Gary S Sachs

      Year
      2021

      Department of Psychiatry, Case Western Reserve School of Medicine, Cleveland, and University Hospitals Cleveland Medical Center, Cleveland (Calabrese); Intra-Cellular Therapies, Inc., New York (Durgam, Satlin [formerly], Vanover [formerly], Davis, Chen, Kozauer, Mates); Massachusetts General Hospital, Boston, and Signant Health, Plymouth Meeting, Pa. (Sachs).

      Massachusetts General Hospital, Boston, USA

      2019

      Harvard University Massachusetts General Hospital, Boston, MA, USA

      2018

      Depression and Bipolar Support Alliance (DBSA), Chicago, IL, United States

      Instituto de Informatica, Universidade Federal de Goias, Goiania, GO, Brazil

      Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

      2017

      Department of Psychiatry Harvard Medical School Boston MAUSA

      Massachusetts General Hospital, Boston, MA, USA

      2016

      From the Department of Psychiatry, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland; and the Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston.

      2015

      Dr. Szabo is with Duke University Medical Center, Durham, North Carolina, and Veterans Administration Medical Center, Durham, North Carolina; Dr. Kinon is with Lundbeck LLC, Deerfield, Illinois (Dr. Kinon was with Eli Lilly and Company, Indianapolis, Indiana, when this material was presented); Dr. Brannan is with Takeda Global Research & Development Center, Inc., Deerfield, Illinois; Dr. Krystal is with Duke University Medical Center, Durham, North Carolina; Dr. van Gerven is with Centre for Human Drug Research, Leiden, The Netherlands; Dr. Mahableshwarkar is with Takeda Global Research & Development Center, Inc., Deerfield, Illinois; Dr. Sachs is with Massachusetts General Hospital, Boston, Massachusetts.

      Bipolar Clinic and Research Program at Massachusetts General Hospital, Boston, MA, USA

      2014

      Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114-3117, USA

      2013

      Department of Psychiatry, Harvard Medical School, and the Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston, USA.

      Harvard Medical School, Cambridge, MA, USA

      2012

      Bipolar Clinic and Research Program, Massachusetts General Hospital, 50 Staniford St, 5th Floor, Boston, MA 02114, USA.

      From *Pfizer Inc, New York, NY; †Massachusetts General Hospital, Boston; and ‡Harvard University, Cambridge, MA.

      2011

      Bipolar Clinic and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

      2010

      Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA

      Massachusetts General Hospital and Harvard Medical School, Boston, MA

      2009

      Bipolar Clinic and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

      Massachusetts General Hospital Department of Psychiatry, Boston, MA, 02114, United States

      2008

      MGH Bipolar Clinic and Research Program, Boston, MA, United States

      Department of Psychiatry, Harvard Medical School, Boston, MA, USA

      Massachusetts General Hospital, Bipolar Clinic and Research Program, Boston, MA

      2007

      Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston (Drs Reilly-Harrington, Nierenberg, and Sachs)

      From Massachusetts General Hospital, Harvard Medical School (G.S.S., A.A.N., M.J.O.), and Boston University (M.W.O.) — all in Boston

      2006

      Department of Psychiatry, Harvard-Massachusetts General Hospital, Cambridge, USA.

      Bipolar Clinic and Research Program, Massachusetts General Hospital

      2005

      Harvard Medical School, Massachusetts General Hospital, Bipolar Program, Boston, MA, USA

      2004

      Harvard Bipolar Research Program, Massachussets General Hospital, Harvard Medical School, Boston, MA, USA

      2003

      Harvard Bipolar Research Program, Massachusetts General Hospital, Boston, 02114, USA.

      WACC 815, Massachusetts General Hospital, 15 Parkman Street, Boston, MA 02114, USA

      Dokuz Eylul Medical School, Department of Psychiatry, Izmir, Turkey

      University of Toronto, Scarborough Hospital, Canada

      2002

      Bipolar Research Program, Department of Psychiatry, Massachusetts General Hospital, 50 Staniford Street, Suite 580, Boston, MA 02114, USA.

      2001

      Harvard Medical School, Massachussets General Hospital, Bipolar Clinic and Research Program, Boston, MA, USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Gary S Sachs is among the top experts in the world.
      Concept World rank
      meta analyses rates #1
      stepbd #1
      diagnosed bipolar disorder #1
      studies classic antipsychotics #1
      syndromal symptoms #1
      teas longer duration #1
      dvp monotherapy patients #1
      flexiblydosed cariprazine #1
      doubleblind pilot study #1
      lithium female follow #1
      program bipolar #1
      rates study completers #1
      agents monotherapy #1
      concern previous trials #1
      drug therapy antidepressants #1
      inositol subjects #1
      machine learning ade #1
      depression mood elevation #1
      bipolarity scores #1
      adjunctive treatment agents #1
      ineffective complex chronic #1
      keywords bipolar disorder #1
      bpd china diagnostic #1
      anticonvulsant lamotrigine #1
      stepbd assessment package #1
      bpd groups sensitivity #1
      cpp quantitative analysis #1
      mania treated #1
      blind lithium #1
      bpd mdd diagnosis #1
      mdd bpd groups #1
      mood stabilizer haloperidol #1
      nimh request #1
      patients careful management #1
      antimanic medication prescribing #1
      antidepressant treatment length #1
      sites minority #1
      rated bipolarity #1
      prospective study bpx #1
      abnormal mood symptoms #1
      usual practice costs #1
      testosterone valproic acid #1
      study brexpiprazole #1
      stepbd baseline data #1
      length depressive episodes #1
      cutoff score mdd #1
      endpoint haloperidol patients #1
      incidence weight #1
      static bodyweight #1
      valproate 6 months #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Gary S Sachs

      KOL-Index: 16974

      OBJECTIVE: The study assessed the efficacy and safety of risperidone as an adjunctive agent to mood stabilizers in the treatment of acute mania.

      METHOD: This 3-week randomized, double-blind, placebo-controlled study included 156 bipolar disorder patients with a current manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, risperidone, or haloperidol. The primary efficacy measure was the Young Mania Rating Scale. Other assessments used the Brief ...

      Known for Mood Stabilizer | Acute Mania | Risperidone Haloperidol | Patients Placebo | Efficacy Safety
      KOL-Index: 16863

      BACKGROUND: Lamotrigine has been shown to be an effective treatment for bipolar depression and rapid cycling in placebo-controlled clinical trials. This double-blind, placebo-controlled study was conducted to assess the efficacy and tolerability of lamotrigine and lithium compared with placebo for the prevention of relapse or recurrence of mood episodes in recently manic or hypomanic patients with bipolar I disorder.

      METHODS: After an 8- to 16-week open-label phase during which treatment ...

      Known for Lamotrigine Lithium | Bipolar Disorder | Placebo Time | Mood Episodes | Relapse Recurrence
      KOL-Index: 14335

      BACKGROUND: To examine the risk for psychopathology in offspring at risk for bipolar disorder and the course of psychiatric disorders in these youth.

      METHODS: Using structured diagnostic interviews (Structured Clinical Interview for DSM-IV [SCID] and Kiddie Schedule for Affective Disorders and Schizophrenia [K-SADS]), psychiatric diagnoses of 117 nonreferred offspring of parents with diagnosed bipolar disorder were compared with those of 171 age- and gender-matched offspring of parents ...

      Known for Bipolar Disorder | Offspring Parents | Controlled Study | Risk Psychopathology | Major Depression
      KOL-Index: 14222

      OBJECTIVE: Bipolar disorder is highly comorbid with substance use disorders, and this comorbidity may be associated with a more severe course of illness, but the impact of comorbid substance abuse on recovery from major depressive episodes in these patients has not been adequately examined. The authors hypothesized that comorbid drug and alcohol use disorders would be associated with longer time to recovery in patients with bipolar disorder.

      METHOD: Subjects (N=3,750) with bipolar I or ...

      Known for Bipolar Disorder | Time Recovery | Systematic Treatment | Enhancement Program | Substance Comorbidity
      KOL-Index: 14155

      BACKGROUND: Systematic studies of children and adolescents with a diagnosis of bipolar disorder show that rates of attention-deficit/hyperactivity disorder (ADHD) range from 60% to 90%, but the prevalence and implications of ADHD in adults with bipolar disorder are less clear.

      METHODS: The first consecutive 1000 adults with bipolar disorder enrolled in the National Institute of Mental Health's Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) were assessed for ...

      Known for Bipolar Disorder | Comorbid Adhd | Lifetime Prevalence | Attention Deficit | Systematic Studies
      KOL-Index: 13910

      OBJECTIVE: The authors compared the efficacy of olanzapine and lithium in the prevention of mood episode relapse/recurrence.

      METHOD: Patients with a diagnosis of bipolar disorder (manic/mixed), a history of two or more manic or mixed episodes within 6 years, and a Young Mania Rating Scale total score > or =20 entered the study and received open-label co-treatment with olanzapine and lithium for 6-12 weeks. Those meeting symptomatic remission criteria (Young Mania Rating Scale score < or ...

      Known for Olanzapine Lithium | Bipolar Disorder | Maintenance Treatment | Relapse Recurrence | Weight Gain
      KOL-Index: 13894

      The rates of comorbid personality disorders in patients with panic disorder are reported to be elevated, have an adverse impact on the response to treatment, and increase the likelihood of relapse on treatment discontinuation. We examined the rates of personality disorders in panic disorder patients in a longitudinal, naturalistic study of panic disorder. Of 100 panic disorder patients studied, 42 met criteria for at least one personality disorder as determined by the Personality ...

      Known for Personality Disorder | Patients Panic | Childhood Anxiety | Child Abuse | Comorbidity Depressive
      KOL-Index: 13876

      BACKGROUND: There is evidence that individuals with bipolar disorder exhibit neuropsychological impairments not only during mood episodes but also when they are euthymic. One of the most consistently reported cognitive problems in euthymic individuals with bipolar disorder is an impairment in verbal episodic memory. Verbal learning and memory depend on individuals' ability to organize verbal information appropriately during learning. The purpose of the present study was (i) to determine ...

      Known for Bipolar Disorder | Memory Impairment | Verbal Learning | Ocd Participants | Obsessive Compulsive
      KOL-Index: 13620

      OBJECTIVE: Little is known about clinical features associated with the risk of recurrence in patients with bipolar disorder receiving treatment according to contemporary practice guidelines. The authors looked for the features associated with risk of recurrence.

      METHOD: The authors examined prospective data from a cohort of patients with bipolar disorder participating in the multicenter Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study for up to 24 months. For ...

      Known for Bipolar Disorder | Risk Recurrence | Depressive Episode | Shorter Time | Systematic Treatment
      KOL-Index: 13427

      BACKGROUND: Sleep disturbance in bipolar disorder can be both a risk factor and symptom of mood episodes. However, the associations among sleep and clinical characteristics, function, and quality of life in bipolar disorder have not been fully investigated.

      METHODS: The prevalence of sleep disturbance, duration, and variability, as well as their associations with mood, function, and quality of life, was determined from 2024 bipolar patients enrolled in the National Institute of Mental ...

      Known for Bipolar Disorder | Quality Life | Sleep Disturbance | Systematic Treatment | Enhancement Program
      KOL-Index: 13255

      OBJECTIVE: The effect of lamotrigine maintenance therapy on body weight was assessed retrospectively in analyses of data from two double-blind, placebo- and lithium-controlled, 18-month studies in patients with bipolar I disorder (n = 227 for lamotrigine, 190 for placebo, 166 for lithium).

      METHODS: Endpoints included mean change in weight, the percentage of patients with > or = 7% change (increase, decrease, fluctuation) in weight, and the percentage of patients with weight-related ...

      Known for Lamotrigine Lithium | Patients Bipolar Disorder | Maintenance Treatment | Weight Week | Antipsychotic Agents
      KOL-Index: 12819

      BACKGROUND: A 6-week double-blind, randomized, placebo-controlled trial was conducted to determine the efficacy of combined therapy with olanzapine and either valproate or lithium compared with valproate or lithium alone in treating acute manic or mixed bipolar episodes.

      METHODS: The primary objective was to evaluate the efficacy of olanzapine (5-20 mg/d) vs placebo when added to ongoing mood-stabilizer therapy as measured by reductions in Young Mania Rating Scale (YMRS) scores. Patients ...

      Known for Lithium Treatment | Efficacy Olanzapine | Patients Bipolar Disorder | Partially Nonresponsive | Mixed Episodes

      Key People For Bipolar Disorder

      Top KOLs in the world
      #1
      Eduardo Eduard
      bipolar disorder cognitive impairment acute mania
      #2
      Robert M Post
      bipolar disorder affective illness depressed patients
      #3
      Susan L McElroy
      bipolar disorder binge eating bulimia nervosa
      #4
      Paul E Keck
      bipolar disorder acute mania united states
      #5
      Joseph R Calabrese
      bipolar disorder suicidal ideation rapid cycling
      #6
      Gary S Sachs
      bipolar disorder rapid cycling acute mania

      Department of Psychiatry, Case Western Reserve School of Medicine, Cleveland, and University Hospitals Cleveland Medical Center, Cleveland (Calabrese); Intra-Cellular Therapies, Inc., New York (Durgam, Satlin [formerly], Vanover [formerly], Davis, Ch

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.